https://nova.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50457 Wed 28 Feb 2024 15:09:41 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30558 40% of publications that have used tamoxifen to generate conditional knockouts have not reported even the minimum appropriate controls. To highlight the importance of this issue, the present study investigated the long-term impacts of different doses of a single systemic tamoxifen injection on the testis and the wider endocrine system. We found that a single dose of tamoxifen less than 10% of the mean dose used for recombination induction, caused adverse effects to the testis and to the reproductive endocrine system that persisted long-term. These data raise significant concerns about the widespread use of tamoxifen induction of recombination, and highlight the importance of including appropriate controls in all pathophysiological studies using this means of induction.]]> Wed 11 Apr 2018 17:20:19 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29519 .05). In both treatment arms, we observed significant trends for lower adherence with increasing severity for all symptoms (P < .01) except headaches (P = .054). Conclusion: In the IBIS-I trial, experiencing predefined symptoms in the first 6 months reduced long-term adherence. Effects were similar between treatment arms, suggesting that women were attributing age-related symptoms to preventive therapy. Interventions were required to support symptom management.]]> Wed 11 Apr 2018 12:50:17 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28241 Wed 11 Apr 2018 10:43:55 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:23398 Wed 11 Apr 2018 10:02:15 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19496 Wed 11 Apr 2018 09:40:34 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50025 Tue 27 Jun 2023 16:47:40 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24211 Thu 28 Oct 2021 13:03:31 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:165 Thu 25 Jul 2013 09:09:46 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25887 Thu 21 Jul 2022 15:37:04 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24206 Thu 04 Nov 2021 10:38:26 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:8225 Sat 24 Mar 2018 08:40:37 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7415 Sat 24 Mar 2018 08:40:26 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:11280 35 kg/m2) at baseline had more recurrences than those women with a low BMI (BMI < 23 kg/m2; adjusted hazard ratio [HR], 1.39; 95% CI, 1.06 to 1.82; Pheterogeneity = .03) and significantly more distant recurrences (adjusted HR, 1.46; 95% CI, 1.07 to 1.61; Pheterogeneity = .01). Overall, the relative benefit of anastrozole versus tamoxifen was nonsignificantly better in thin women compared to overweight women. Conclusion: These results confirm the poorer prognosis of obese women with early-stage breast cancer. Recurrence rates were lower for anastrozole than tamoxifen for all BMI quintiles. Our results suggest that the relative efficacy of anastrozole compared to tamoxifen is greater in thin postmenopausal women and higher doses or more complete inhibitors might be more effective in overweight women, but this requires independent confirmation.]]> Sat 24 Mar 2018 08:12:44 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:11225 Sat 24 Mar 2018 08:11:14 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:11170 Sat 24 Mar 2018 08:10:42 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:11140 Sat 24 Mar 2018 08:10:29 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:16697 Sat 24 Mar 2018 08:06:52 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17176 Sat 24 Mar 2018 08:06:32 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17172 Sat 24 Mar 2018 08:06:31 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19000 Sat 24 Mar 2018 08:05:34 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17517 Sat 24 Mar 2018 08:03:50 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:21497 Sat 24 Mar 2018 08:03:39 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17404 Sat 24 Mar 2018 08:01:40 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17734 Sat 24 Mar 2018 07:57:38 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17782 Sat 24 Mar 2018 07:57:23 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17752 Sat 24 Mar 2018 07:57:20 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:5453 Sat 24 Mar 2018 07:48:12 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:5363 Sat 24 Mar 2018 07:43:57 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:4862 30 kg/m²) reported more joint symptoms than women with a BMI of 25-30 kg/m² or those with a BMI <25 kg/m² (504 of 1354 women [37·2%] vs 502 of 1926 women [31·3%; OR 1·01 (0·88-1·16)] vs 592 of 1908 women [31·0%; OR 1·32 (1·14-1·53)]) and women on anastrozole reported more joint symptoms compared with those on tamoxifen (949 of 2698 women [35·2%] vs 829 of 2735 women [30·3%]; OR 1·25 [1·11-1·40]). All significant risk factors from the univariate analysis were included in a multivariate analysis and remained significant with little change. Interpretation: In this trial, the major risk factors for developing joint symptoms were previous HRT, hormone-receptor positivity, previous chemotherapy, obesity, and treatment with anastrozole. Discussion of identified risk factors is appropriate when counselling women before initiation of adjuvant hormonal treatment. Funding: This study was funded by Cancer Research UK and AstraZeneca (Macclesfield, UK).]]> Sat 24 Mar 2018 07:18:52 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:23662 Sat 24 Mar 2018 07:16:50 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:23220 Sat 24 Mar 2018 07:10:38 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32264 .05). In both treatment arms, we observed significant trends for lower adherence with increasing severity for all symptoms (P < .01) except headaches (P = .054). Conclusion: In the IBIS-I trial, experiencing predefined symptoms in the first 6 months reduced long-term adherence. Effects were similar between treatment arms, suggesting that women were attributing age-related symptoms to preventive therapy. Interventions were required to support symptom management.]]> Mon 23 Sep 2019 11:46:30 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:5127 Fri 05 Jul 2024 12:28:32 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30333 Fri 01 Apr 2022 09:24:55 AEDT ]]>